摘要
新生血管性青光眼(NVG)是一种由多种疾病导致视网膜缺血缺氧而发生的继发性青光眼,研究发现其病因与VEGF有关。目前,抗VEGF药物作为治疗NVG的手段之一,已成为现阶段青光眼研究领域的热点,为提高NVG疗效开辟了新的途径。本文就有关NVG病理生理基础与临床过程,包括Bevacizumab、Ranibizumab、Pegaptanib及Aflibercept在内的4种抗VEGF药物的基础研究,抗VEGF药物在NVG及滤过手术抗瘢痕治疗中应用的国内外研究进展进行综述,以期为临床治疗NVG、提高手术成功率提供参考。
Neovascular glaucoma (NVG) is a group of secondary glaucoma which led by a variety of diseases that have anoxia or ischemia to the retina.Some studies have found that the etiology was related to the vascular endothelial growth factor(VEGF).At present,anti-VEGF as a treatment method to NVG,has become an important advancc in the field of glaucoma research,which established a new way to improve the prognosis.This review mainly focused on the pathophysiologic basis and clinical research of NVG,fundamental research and applications about four kinds of anti-VEGF agents (Bevacizumab,Ranibizumab,Pegaptanib and Aflibercept) and application of treatment of NVG and anti-scarring in filtering surgery.The review also provided references for the clinical treatment of NVG and improving the success rate of operation.
出处
《中华眼科杂志》
CAS
CSCD
北大核心
2015年第4期314-318,共5页
Chinese Journal of Ophthalmology
关键词
青光眼
新生血管性
滤过外科手术
血管生成抑制剂
抗体
单克隆
人
血管内皮生长因子A
Glaucoma;neovascular
Filtering surgery
Vascular endothelial growth factor A
Angiogenesis inhibitors
Antibodies;monoclonal;humanized